Emerging concepts and therapeutics strategies for the treatment of brain tumors

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 8, 2014, Pages 1063-1064

  Chen, Jianliang ^a   Yakisich, Juan Sebastian ^b  

^a Department of Neurosurgery The 4th Hospital of Shenzhen the Affiliated Hospital of Goandong Medical College   (China)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Blood brain barrier; Clinical trials; Concepts; Glioma; Immunotherapy; Microenvironment; Phenotype; Stem cell theory; Stem cells; Stemness; Therapy

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CD133 ANTIGEN; CHEMOKINE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; MYC PROTEIN; NANOPARTICLE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SALINOMYCIN; TAPASIN; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT;

BRAIN TUMOR; CANCER PROGNOSIS; CANCER STEM CELL; EDITORIAL; GLIOBLASTOMA; HUMAN; IMMUNOTHERAPY; OVERALL SURVIVAL; QUALITY OF LIFE; SIGNAL TRANSDUCTION; BRAIN NEOPLASMS; GLIOMA;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; GLIOMA; HUMANS; IMMUNOTHERAPY;

EID: 84907163549     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152061408140908113346     Document Type: Editorial

References (21)

1. Jelsma, R.; Bucy, P.C. The treatment of glioblastoma multiforme of the brain. J. Neurosurg., 1967, 27 (5), 388-400.
2. Holland, E.C. Glioblastoma multiforme: The terminator. Proc. Nat. Acad. Sci. USA, 2000, 97 (12), 6242-6244.
3. Stupp, R.; Mason, W.P.; Van Den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R.C.; Ludwin, S.K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J.G.; Eisenhauer, E.; Mirimanoff, R.O. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups: National Cancer Institute of Canada Clinical Trials Group Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352 (10), 987-996.
4. Stupp, R.; Tonn, J.C.; Brada, M.; Pentheroudakis, G.; ESMO Guidelines Working Group. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol., 2010, Suppl 5, V190-193.
5. Kast, R.E.; Boockvar, J.A.; Bruning, A.; Cappello, F.; Chang, W.W.; Cvek, B.; Dou, Q.P.; Duenas-Gonzalez, A.; Efferth, T.; Focosi, D.; Ghaffari, S.H.; Karpel-Massler, G.; Ketola, K.; Khoshnevisan, A.; Keizman, D.; Magné, N.; Marosi, C.; McDonald, K.; Muñoz, M.; Paranjpe, A.; Pourgholami, M.H.; Sardi, I.; Sella, A.; Srivenugopal, K.S.; Tuccori, M.; Wang, W.; Wirtz, C.R.; Halatsch, M.E. A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget, 2013, 4 (4), 502-530.
6. Alexandru, D.; Jadus, M.R.; Hsu, F.P.; Stathopoulos, A.; Bota, D.A. Selective therapeutic targeting of malignant glioma stem cells. Anticancer Agents Med Chem, 2013, In Press.
7. Christel Herold-Mende, C.; Mock, A. Microenvironment and brain tumor stem cell maintanance: Impact of the niche. Anticancer Agents Med. Chem., 2013, In Press.
8. Beier, C.P.; Kumar, P.; Meyer, K.; Leukel, P.; Bruttel, V.; Aschenbrenner, I.; Riemenschneider, M.J.; Fragoulis, A.; Rümmele, P.; Lamszus, K.; Schulz, J.B.; Weis, J.; Bogdahn, U.; Wischhusen, J.; Hau, P.; Spang, R.; Beier, D. The cancer stem cell subtype determines immune infiltration of glioblastoma. Stem Cells Dev., 2012, 21 (15), 2753-2761.
9. Thuring, C.; Geironson, L.; Paulsson, K. Tapasin and human leukocyte class I dysregulation correlates with survival in glioblastoma multiforme. Anticancer Agents Med. Chem., 2013, In Press.
10. Darabi, A.; Thuring, C.; Paulsson, K.M. Immune responses against malignant brain tumors - considerations for successful immunotherapy. Anticancer Agents Med. Chem., 2013, In Press.
11. Ma, C.; Zhao, G.; Cruz, M.H.; Sidén, A.; Yakisich, J.S. Translational gap in glioma research. Anticancer Agents Med. Chem., 2013, In Press.
12. Wang, Z.; Sun, H.; Yakisich, J.S. Overcoming the blood-brain barrier for chemotherapy: limitations, challenges and rising problems. Anticancer Agents Med. Chem., 2013, In Press.
13. Darlix, A.; Baumann, C.; Lorgis, V.; Ghiringhelli, F.; Blonski, M.; Chauffert, B.; Zouaoui, S.; Pinelli, C.; Rech, F.; Beauchesne, P.; Taillandier, L. Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. Anticancer Res., 2013, 33 (8), 3467-3474.
14. Delwar, Z.M.; Avramidis, D.; Siden, Å.; Cruz, M.; Paulsson, K.; Yakisich, J.S. Low concentration of salinomycin prevents regrowth and partially depletes human glioma cells surviving high concentrations of alkylating agents. Clin. Cancer Drugs, 2014, In Press.
15. Delwar, Z.M.; Avramidis, D.; Siden, Å.; Cruz, M.; Yakisich, J.S. Depletion of drug-surviving glioma cells by a second phase treatment with low concentration of salinomycin. Drug Ther., Stud., 2011, 1(e7), 21-25.
16. Cruz, M.; Siden, Å.; Tasat, D.R.; Yakisich, J.S. Are all glioma cells cancer stem cells? J. Cancer Sci. Ther., 2010, 2, 100-106.
17. Li, Y.; Laterra, J. Cancer stem cells: Distinct entities or dynamically regulated phenotypes? Cancer Res., 2012, 72 (3), 576-580.
18. Vermeulen, L.; De Sousa E.; Melo, F.; Richel, D.J.; Medema, J.P. The developing cancer stem-cell model: Clinical challenges and opportunities. Lancet Oncol., 2012, 13 (2), e83-89.
19. Khan, Z.; Shervington, A.; Munje, C.; Shervington, L. The complexity of identifying cancer stem cell biomarkers. Cancer Invest., 2013, 31 (6), 404-411.
20. Cruz, M.H.; Siden, A.; Calaf, G.M.; Delwar, Z.M.; Yakisich, J.S. The stemness phenotype model. 2012, 2012, 392-647.
21. Schonberg, D.L.; Lubelski, D.; Miller, T.E.; Rich, J.N. Brain tumor stem cells: Molecular characteristics and their impact on therapy. Mol. Aspects Med., 2013, In Press.